Results from the present study suggest that a combination of S1PR1 antagonist with VEGF-VEGFR2 inhibitors could represent the first step toward treating VEGFR2 refractory tumors and prove relevant in other cancers driven by VEGF-VEGFR2 signaling. The gene discussed is VEGFA; the disease is cancer.